Ratings Sabra Health Care REIT, Inc.

Equities

SBRA

US78573L1061

Real-time Estimate Cboe BZX 01:05:21 2024-06-05 pm EDT 5-day change 1st Jan Change
14.54 USD -0.38% Intraday chart for Sabra Health Care REIT, Inc. +3.19% +1.89%

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
  • Sales forecast by analysts have been recently revised upwards.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • One of the major weak points of the company is its financial situation.
  • With a 2024 P/E ratio at 25.79 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

1st Jan change Capi. Investor Rating ESG Refinitiv
+1.89% 3.38B
C+
+16.71% 62.48B
A-
+0.34% 20.2B
A-
+7.44% 8.11B
B
-5.80% 6.14B
B-
+17.05% 3.78B
C-
+13.34% 3.31B
C
-5.34% 3.11B
B+
+19.70% 2.91B
C-
-13.94% 2.54B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SBRA Stock
  4. Ratings Sabra Health Care REIT, Inc.